Everything below concerns lyophilization. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-27. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
== Causes == It is mainly unknown what causes sJIA. There have been reports of seasonal fluctuations in the incidence of sJIA in some places but not in others. Although it has frequently been claimed that infectious organisms cause the condition to manifest, microbiologic and virologic analyses are unable to pinpoint a single agent as the cause. Since a negative septic screen is required for the diagnosis, sJIA is not an infectious disease by definition. There is evidence that suggests a genetic predisposition plays a role in the etiology of sJIA.
==== Private-sector whistleblowing ==== Private-sector whistleblowing is arguably more prevalent and suppressed in society today. An example of private sector whistleblowing is when an employee reports to someone in a higher position such as a manager or to external factors, such as their lawyer or the police. Whistleblowing in the private sector is typically not high-profile or openly discussed in major news outlets, though occasionally, third parties expose human rights violations and exploitation of workers. Many governments attempt to protect such whistleblowers. In the United States, for example, there are organizations such as the United States Department of Labor (DOL) and laws such as the Sarbanes-Oxley Act and the United States Federal Sentencing Guidelines for Organizations (FSGO) that protect whistleblowers in the private sector. Thus, despite government efforts to help regulate the private sector, the employees must still weigh their options. They may expose the company and stand on the moral and ethical high ground, but lose their job, their reputation, and potentially the ability to be employed again. According to a study at the University of Pennsylvania, out of three hundred whistleblowers studied, sixty-nine percent had foregone that exact situation. They were either fired or forced to retire after taking the ethical high ground. It is outcomes like these that make it all that much harder to accurately track the prevalence of whistleblowing in the private sector.
=== Functional brain imaging === Usually the gamma-emitting tracer used in functional brain imaging is 99mTc-HMPAO (hexamethylpropylene amine oxime, exametazime). The similar 99mTc-EC tracer may also be used. These molecules are preferentially distributed to regions of high brain blood flow, and act to assess brain metabolism regionally, in an attempt to diagnose and differentiate the different causal pathologies of dementia. When used with the 3-D SPECT technique, they compete with brain FDG-PET scans and fMRI brain scans as techniques to map the regional metabolic rate of brain tissue.
On 2 September 1919, the Francesco Saverio Nitti government issued the Visocchi Decree (named after the Minister of Agriculture, Achille Visocchi), which gave prefects the power to temporarily assign uncultivated land for four years to peasants formed in legally constituted leagues or agrarian bodies. A permit issued by a committee composed equally of peasant and landowner representatives, under prefectorial control, was required to obtain the assignment, which specified the duration of occupation and the rental price (paid by the peasants). However, seven months later, the redistribution had limited effects: only an estimated 27,000 hectares were allocated. The decree was criticized by both conservatives and socialists: Arrigo Serpieri, later minister of agriculture in the Fascist period, judged the measure “one of the most infamous of the postwar period”, while socialist Filippo Turati deemed it too “timid”.
Sam Chun Dang Pharm Co., Ltd. (Korean: 삼천당제약; Hanja: 三千堂製藥; RR: Samcheondang jeyak), commonly abbreviated as SCD, is a South Korean pharmaceutical company engaged in the development, manufacturing, and sale of prescription medicines. Founded in 1943, the company is headquartered in Seocho-gu, Seoul, with manufacturing operations at the Hyannam Pharmaceutical Industrial Complex in Hwaseong, Gyeonggi Province. SCD is listed on the Korea Exchange (KRX: 000250). The company is best known for its ophthalmic products, which accounts for approximately half of its total revenues, and has attracted attention for its development of an aflibercept biosimilar (SCD411) and an oral semaglutide generic.
Sources: en.wikipedia.org
1808: Anna Sundström began assisting Jacob Berzelius in his laboratory, becoming one of the first Swedish women chemists. 1809: Italian pharmacist Sabina Baldoncelli earned her university degree in pharmacy but was allowed to work only in the Italian orphanage where she resided. 1815: English archaeologist and antiquarian Lady Hester Stanhope used a medieval Italian manuscript to locate a promising archaeological site in Ashkelon, becoming the first archaeologist to begin an excavation in the Palestinian region. It was one of the earliest examples of the use of textual sources in field archaeology. 1816: French mathematician and physicist Sophie Germain became the first woman to win a prize from the Paris Academy of Sciences for her work on elasticity theory. 1823: English palaeontologist and fossil collector Mary Anning discovered the first complete Plesiosaurus. 1831: Italian botanist Elisabetta Fiorini Mazzanti published her best-known work Specimen Bryologiae Romanae. 1830–1837: Belgian botanist Marie-Anne Libert published her four-volume Plantae cryptogamicae des Ardennes, a collection of 400 species of mosses, ferns, lichen, algae and fungi from the Ardennes region. Her contributions to systemic cryptogamic studies were formally recognized by Prussian king Friedrich Wilhelm III, and Libert received a gold medal of merit. 1832: French marine biologist Jeanne Villepreux-Power invented the first glass aquarium, using it to assist in her scientific observations of Argonauta argo.
==== Hypogonadism ==== An absolute deficiency in androgen production due to primary or secondary hypogonadism can cause gynecomastia. Primary hypogonadism results when there is damage to the testes (due to radiation, chemotherapy, infections, trauma, etc.), leading to impaired androgen production. It can also be caused by chromosomal abnormality seen in Klinefelter syndrome, which is associated with gynecomastia in about 80% of cases. Secondary hypogonadism results when there is damage to the hypothalamus or pituitary (due to radiation, chemotherapy, infection, trauma, etc.), and similarly leads to impaired androgen production. The net effect is reduced androgen production while serum estrogen levels (from peripheral aromatization of androgens) remain unaffected. The lack of androgen-mediated inhibition of breast tissue proliferation, combined with relative estrogen excess, results in gynecomastia.
== Treatment == Disease progression may be slowed with immunosuppressives and other medications, and esophageal reflux, pulmonary hypertension and Raynaud phenomenon may benefit from symptomatic treatment. However, there is no cure for this disease as there is no cure for scleroderma in general.
=== Commercial development === By the late 1960s, increasing volumes of whey had become an economic and environmental problem for the New Zealand dairy industry, creating an incentive to develop higher-value uses for its whey protein. In September 1969, Dr. Alex Malaspina, vice-president responsible for new product development and quality control at The Coca-Cola Export Corporation, approached the New Zealand Dairy Board in search of a reliable supply of soluble whey protein for acidic, carbonated beverages, with potential demand estimated at as much as 10,000 tons annually. At the time, the New Zealand industry did not know how to manufacture such a product because its existing heat-precipitated whey protein was insoluble and unsuitable for beverages. The Dairy Board and the New Zealand Dairy Research Institute (NZDRI) investigated several separation technologies, and Malaspina, Dr. R. Fenton-May from Coca-Cola, and NZDRI engineer Dave Woodhams examined ultrafiltration, reverse osmosis, and other processes in the United States. Woodhams recommended ultrafiltration, and in September 1970 NZDRI produced a whey protein concentrate containing 65% protein and meeting Coca-Cola's requirements for beverage solubility and clarity. Malaspina subsequently worked with Brazilian food scientist Roberto H. Moretti on a process for producing whey protein suitable for acidic beverages. Their U.S.
Rosenberg states, "These mechanisms reveal a picture of highly regulated mutagenesis, up-regulated temporally by stress responses and activated when cells/organisms are maladapted to their environments—when stressed—potentially accelerating adaptation." Since they are self-induced mutagenic mechanisms that increase the adaptation rate of organisms, they have some times been named as adaptive mutagenesis mechanisms, and include the SOS response in bacteria, ectopic intrachromosomal recombination and other chromosomal events such as duplications.
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.